These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10944799)

  • 21. Determinant flanking regions and the design of appropriate vaccines.
    Soares L; Deng H; Grewal IS; Kumar V; Miller A; Moudgil KD; Palmer M; Sercarz EE
    Ann N Y Acad Sci; 1995 May; 754():48-56. PubMed ID: 7625680
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
    Stacey KJ; Blackwell JM
    Infect Immun; 1999 Aug; 67(8):3719-26. PubMed ID: 10417129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression cloning of a protective Leishmania antigen.
    Mougneau E; Altare F; Wakil AE; Zheng S; Coppola T; Wang ZE; Waldmann R; Locksley RM; Glaichenhaus N
    Science; 1995 Apr; 268(5210):563-6. PubMed ID: 7725103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
    Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CpG oligodeoxynucleotides as vaccine adjuvants in primates.
    Verthelyi D; Kenney RT; Seder RA; Gam AA; Friedag B; Klinman DM
    J Immunol; 2002 Feb; 168(4):1659-63. PubMed ID: 11823494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice.
    Jaafari MR; Ghafarian A; Farrokh-Gisour A; Samiei A; Kheiri MT; Mahboudi F; Barkhordari F; Khamesipour A; McMaster WR
    Vaccine; 2006 Jul; 24(29-30):5708-17. PubMed ID: 16740346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
    Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
    Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
    Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection.
    Sjölander A; Baldwin TM; Curtis JM; Bengtsson KL; Handman E
    Vaccine; 1998 Dec; 16(20):2077-84. PubMed ID: 9796067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection.
    Rivier D; Bovay P; Shah R; Didisheim S; Mauël J
    Parasite Immunol; 1999 Sep; 21(9):461-73. PubMed ID: 10476055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fragments of antigen-loaded dendritic cells (DC) and DC-derived exosomes induce protective immunity against Leishmania major.
    Schnitzer JK; Berzel S; Fajardo-Moser M; Remer KA; Moll H
    Vaccine; 2010 Aug; 28(36):5785-93. PubMed ID: 20615489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skin-derived macrophages from Leishmania major-susceptible mice exhibit interleukin-12- and interferon-gamma-independent nitric oxide production and parasite killing after treatment with immunostimulatory DNA.
    von Stebut E; Belkaid Y; Nguyen B; Wilson M; Sacks DL; Udey MC
    J Invest Dermatol; 2002 Sep; 119(3):621-8. PubMed ID: 12230504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
    Gurunathan S; Stobie L; Prussin C; Sacks DL; Glaichenhaus N; Iwasaki A; Fowell DJ; Locksley RM; Chang JT; Wu CY; Seder RA
    J Immunol; 2000 Jul; 165(2):915-24. PubMed ID: 10878366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.
    Handman E; Symons FM; Baldwin TM; Curtis JM; Scheerlinck JP
    Infect Immun; 1995 Nov; 63(11):4261-7. PubMed ID: 7591056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [LACK protein of Leishmania major: a pivotal antigen in the immune relation between host and parasite].
    Gangneux JP
    Sante; 1997; 7(6):425. PubMed ID: 9503502
    [No Abstract]   [Full Text] [Related]  

  • 37. Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis.
    Tsagozis P; Karagouni E; Dotsika E
    Int J Immunopathol Pharmacol; 2004; 17(3):343-52. PubMed ID: 15461868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
    Gurunathan S; Prussin C; Sacks DL; Seder RA
    Nat Med; 1998 Dec; 4(12):1409-15. PubMed ID: 9846579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
    Piedrafita D; Xu D; Hunter D; Harrison RA; Liew FY
    J Immunol; 1999 Aug; 163(3):1467-72. PubMed ID: 10415048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.